GDRX
$2.23
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.
Intraday
Recent News
HIMS Expands Personalized Digital Healthcare Access and Services
Hims & Hers expands its digital care platform with labs tracking, multi-cancer screening access and broader treatments as it scales personalized healthcare globally.
2 Small-Cap Stocks with Competitive Advantages and 1 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance
GoodRx Holdings, Inc. recently reported fourth-quarter 2025 revenue of US$194.79 million and full-year revenue of US$796.85 million, alongside the launch of GoodRx Employer Direct to help employers subsidize high-cost brand medications such as GLP-1s. Together with 2026 revenue guidance of US$750 million to US$780 million, a large completed share repurchase program, and a new ESOP-related shelf registration, these updates highlight GoodRx’s efforts to balance growth initiatives with capital...